1672.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 04:09):

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally...

Stats
Today's Volume	456 000
Average Volume	1.09M
Market Cap	1.37B
EPS	HKD0 ( 2023-08-22 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-9.07
ATR14	HKD0.00500 (0.37%)

Volume Correlation

Long: 0.01 (neutral)

Short: 0.00 (neutral)

Signal:(67.608) Neutral

Ascletis Pharma Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ascletis Pharma Inc Correlation - Currency/Commodity

0.76
( moderate )

-0.54
( weak negative )

0.00
( neutral )

-0.27
( neutral )

Ascletis Pharma Inc Financials

Annual	2023
Revenue:	HKD56.60M
Gross Profit:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

Q4	2023
Revenue:	HKD5.05M
Gross Profit:	HKD-6.32M (-125.17 %)
EPS:	HKD-0.0604

Q3	2023
Revenue:	HKD5.05M
Gross Profit:	HKD-6.32M (-125.17 %)
EPS:	HKD-0.0604

Q2	2023
Revenue:	HKD23.25M
Gross Profit:	HKD19.31M (83.04 %)
EPS:	HKD-0.00760

Financial Reports:

No articles found.

Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.